Patrick B Trotter1,2, Dominic M Summers1,2, Ines Ushiro-Lumb2, Matthew Robb2, J Andrew Bradley1, James Powell3, Christopher J E Watson1, James Neuberger4. 1. National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the NIHR Blood and Transplant Research Unit (BTRU) in Organ Donation and Transplantation at the University of Cambridge in collaboration with Newcastle University and in partnership with NHS Blood and Transplant (NHSBT), United Kingdom. 2. Organ Donation and Transplantation Directorate, NHS Blood and Transplant, United Kingdom. 3. Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom. 4. Hepatic-Pancreatico-Biliary Surgical Services and Edinburgh Transplant Unit, Royal Infirmary of Edinburgh, United Kingdom.
Abstract
BACKGROUND: Organs from hepatitis C virus (HCV) seropositive (HCVpos) individuals are seldom used for transplantation because of the risk of disease transmission. Because transmitted HCV is now amenable to effective treatment, we estimated the potential impact of using HCVpos deceased donor organs for transplantation. METHODS: The Potential Donor Audit of patients (<80 years) dying in UK critical care units and the UK Transplant Registry was searched to identify HCVpos potential and proceeding deceased donors. Donor organ quality was assessed using validated donor organ quality indices. Cost analysis was performed by comparing the cumulative cost of direct-acting antivirals with hemodialysis and renal transplantation. RESULTS: Between 2009 and 2016, 120 patients identified from the Potential Donor Audit were not considered as potential donors because of the presence of HCV. Between 2000 and 2015, 244 HCVpos potential deceased donors were identified from the UK Transplant Registry, and 76 (31%) proceeded to donation, resulting in 63 liver, 27 kidney, and 2 heart transplants. Recipient and graft survival was not adversely impacted by donor HCVpos status. Most (69%) offered organs were declined because of positive virology although their quality was similar to that of other transplanted organs. The additional costs of treating recipients exposed to HCV by receiving a HCVpos kidney was cost-neutral with dialysis 5 years from transplantation. CONCLUSIONS: HCVpos donors represent a potential source of organs for HCV seronegative recipients as many good quality HCVpos donor organs are not currently used for transplantation. This change in practice may increase access to transplantation without having an adverse effect on transplant outcome.
BACKGROUND: Organs from hepatitis C virus (HCV) seropositive (HCVpos) individuals are seldom used for transplantation because of the risk of disease transmission. Because transmitted HCV is now amenable to effective treatment, we estimated the potential impact of using HCVpos deceased donor organs for transplantation. METHODS: The Potential Donor Audit of patients (<80 years) dying in UK critical care units and the UK Transplant Registry was searched to identify HCVpos potential and proceeding deceased donors. Donor organ quality was assessed using validated donor organ quality indices. Cost analysis was performed by comparing the cumulative cost of direct-acting antivirals with hemodialysis and renal transplantation. RESULTS: Between 2009 and 2016, 120 patients identified from the Potential Donor Audit were not considered as potential donors because of the presence of HCV. Between 2000 and 2015, 244 HCVpos potential deceased donors were identified from the UK Transplant Registry, and 76 (31%) proceeded to donation, resulting in 63 liver, 27 kidney, and 2 heart transplants. Recipient and graft survival was not adversely impacted by donor HCVpos status. Most (69%) offered organs were declined because of positive virology although their quality was similar to that of other transplanted organs. The additional costs of treating recipients exposed to HCV by receiving a HCVpos kidney was cost-neutral with dialysis 5 years from transplantation. CONCLUSIONS: HCVpos donors represent a potential source of organs for HCV seronegative recipients as many good quality HCVpos donor organs are not currently used for transplantation. This change in practice may increase access to transplantation without having an adverse effect on transplant outcome.
Authors: Mary G Bowring; Lauren M Kucirka; Allan B Massie; Tanveen Ishaque; Sunjae Bae; Ashton A Shaffer; Jacqueline Garonzik Wang; Mark Sulkowski; Niraj Desai; Dorry L Segev; Christine M Durand Journal: Transplantation Date: 2018-12 Impact factor: 4.939
Authors: Christian Corbin Frye; Jason M Gauthier; Amit Bery; William D Gerull; Deniz B Morkan; Jingxia Liu; M Shea Harrison; Yuriko Terada; Judith E Van Zanden; Gary F Marklin; Michael K Pasque; Ruben G Nava; Bryan F Meyers; Alexander G Patterson; Benjamin D Kozower; Ramsey Hachem; Derek Byers; Chad Witt; Hrishikesh Kulkarni; Daniel Kreisel; Varun Puri Journal: Clin Transplant Date: 2020-12-14 Impact factor: 2.863
Authors: Samuel Chan; Nicole M Isbel; Carmel M Hawley; Scott B Campbell; Katrina L Campbell; Mark Morrison; Ross S Francis; E Geoffrey Playford; David W Johnson Journal: Medicina (Kaunas) Date: 2019-10-04 Impact factor: 2.430
Authors: Jennifer Wellington; Andrew Ma; Shyam Kottilil; Bharath Ravichandran; Jennifer Husson; David Bruno; Eleanor Wilson Journal: Viruses Date: 2021-09-14 Impact factor: 5.048